June 15, 2023 5:02pm

Just remember, the cell and gene therapy sector is viewed as sensitive to swings in the health of the economy

Subscription is coming, it is not conscription but, an offer to join our collective of like-minded investors!  Join me … in the NO spin zone.

If you want facts to expose share pricing facts to save your portfolio for deliberate decisions, bookmark this site!

We are about to face a prisoner’s dilemma- a situation wherein individuals acting in their own best interest do not achieve the optimal outcome for the overall group.

If I have learned one thing as a former research analyst in a venture and public fund, operating executive, adjunct (MBA) business school professor now a journalist; it is that your life and your portfolio are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed UP +428.73 points (+1.26%), the S&P closed UP +53.25 points (+1.22%) while the Nasdaq closed UP +156.34 points (+1.15%)

 

Henry’omics:

We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes on Thursday rallied, as investors bet the Fed was close to done raising rates after the central bank this week paused its rate-hiking campaign following 10 consecutive increases.

Thursday’s gains brought the S&P 500 and Nasdaq to their highest intraday levels since April 2022.

Additional economic data releases Thursday morning gave investors and policymakers better insight on the strength of the labor market and consumer spending. <CNBC>

Economic Data Docket: Weekly jobless claims numbers were slightly above estimates at 262,000 compared to a Dow Jones estimate of 245,000, while retail sales ticked up 0.3%.

 

Wednesday (6/15) … RegMed Investors’ (RMi) pre-open: “hang on, share pricing is a tug-of-war and a constant. Electronic trading and algorithms will be reversing course and buying back-in: then slap them down by selling into their highs, if you want to sell risk oriented Q2/earnings – soon to be upon investors.” … https://www.regmedinvestors.com/articles/13005

 

RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened – differences …

Thursday’s advance/decline line opened negative at 13 up/ 20 down and 2 flats, stayed negative with 16 up/ 17 down and 3 flats at the mid-day, ending with a positive close of 19 incliners and 16 decliners and 0 flats

 

Key Metrics:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Thursday, the IBB was up +1.16% and the XBI was up +0.36%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Thursday was up +0.61 point or +4.39% at 14.49

 

Closing Down (10 of 16):

  • Sage Therapeutics (SAGE -$1.94 after Wednesday’s -$0.73, Tuesday’s +$1.11 after Monday’s -$1.88),
  • Editas Medicine (EDIT -$1.81 on the heels of an $125 M stock offering),
  • Ultragenyx (RARE -$1.23 after Wednesday’s -$1.94 after Tuesday’s +$0.63),
  • BioLife Solutions (BLFS -$0.39 after Wednesday’s -$1.13),
  • UniQure NV (QURE -$0.37 after Wednesday’s +$0.80 after Monday’s -$0.40)
  • Regenxbio (RGNX-$0.04 after Wednesday’s -$0.54),
  • Caribou Biosciences (CRBU -$0.03),
  • Sangamo Therapeutics (SGMO -$0.03),
  • Homology Medicine (FIXX -$0.03),
  • Bellicum Pharmaceuticals (BLCM -$0.0255 after Wednesday’s +$0.01 and Tuesday’s +$0.01),

Closing Up (10 of 19):

  • Alnylam Pharmaceuticals (ALNY +$3.85 after Wednesday’s +$0.95, Tuesday’s +$4.45 and Monday’s +$2.26),
  • Verve Therapeutics (VERV +$2.74 after Wednesday’s -$1.02 after Tuesday’s +$0.67),
  • Blueprint Medicine (BPMC +$2.13 after Wednesday’s +$0.46 after Tuesday’s +$0.67 and Monday’s -$0.84),
  • Ionis Pharmaceuticals (IONS +$0.87 after Wednesday’s -$1.07),
  • Vericel (VCEL +$0.67),
  • Fate Therapeutics (FATE +$0.38),
  • Intellia Therapeutics (NTLA +$0.37 after Wednesday’s -$0.83, Tuesday’s +$2.42 after Monday’s +$0.37),
  • Voyager Therapeutics (VYGR +$0.24),
  • Beam Therapeutics (BEAM +$0.22),
  • Chinook Therapeutics (KDNY +$0.18),

 

Q2/23 – June

  • Thursday closed positive with 19 incliners, 15 decliners and 0 flat

 

The BOTTOM LINE: I try to keep it simple … and short!

I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

Trading was choppy and volume was heavy having started the session in the depths

Even I paused Thursday, as it was a crap-shoot on share pricing.

I believe, there is a great deal of money on the sidelines of people who had been scared of recession; yet, as the worries go away people are returning to equities.

Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

Yet, there is VALUE out there after electronic trading and algorithms take their toll on share pricing however, it’s about playing or betting and timing of the sector. Even as I had stated, “I wouldn’t be buying … I would be selling into this upside!”

 

The top three (3) performing in the session:

·         Thursday: Alnylam Pharmaceuticals (ALNY) – again, Verve Therapeutics (VERV) and Blueprint Medicine (BPMC) - again

·         Wednesday: Alnylam Pharmaceuticals (ALNY) – again, Blueprint Medicine (BPMC) and AxoGen (AXGN)

·         Tuesday: Alnylam Pharmaceuticals (ALNY) – again, Intellia Therapeutics (NTLA) and Editas Medicine (EDIT)  

·         Monday: Chinook Therapeutics (KDNY), Alnylam Pharmaceuticals (ALNY) and BioLife Solutions (BLFS)

While The worst three (3) in the session:

·         Thursday: Sage Therapeutics (SAGE), Editas medicine (EDIT) and Ultragenyx (RARE)

·         Wednesday: Ultragenyx (RARE), CRISPR Therapeutics (EDIT) and BioLife Solutions (BLFS)

·         Tuesday: Solid Biosciences (SLDB), Chinook Therapeutics (KDNY) and Homology Medicine (FIXX)

·         Monday: Sage Therapeutics (SAGE), CRISPR Therapeutics and Blueprint Medicine (BPMC)

 

WHY (?) do I keep posting, so investors can get a daily update of the sector's share pricing and some individual companies TRUTHS while electronic trading chews on our portfolio edges.

I am definitely considered a contrarian depending on the session – one has to be a watcher of the ups and downs as well as measurer of sentiment. I am also a NO trust investor but, a validate and verify journalist/analyst.

Check your portfolio reports: Vanguard Group was fined and censured by the Financial Industry Regulatory Authority (FINRA) for errors appearing in about 8.5 million customer account statements.

 

The NO spin zone! U.S. public shareholders deserve accountability …

 

Biostage (OTCQB: BSTG) … so many issues from the past as many of those “miscreant management” members are still employed!

Thursday closed up +$0.11 with 1,001 shares traded after Wednesday closed up +$0.11 with 2,899 shares traded, Tuesday closed FLAT with 20 shares traded, Monday closed FLAT with 116 shares traded, Friday closed FLAT with 0 shares traded, and last Thursday closed down -$0.11 with 301 shares traded, <3-month average =857 shares>

·         Biostage (OTCQB: BSTG) finally announced a clinical trial initiation for an IND that was approved on 3/20/2020 – what’s with the time (3 years and 2 months) interval?

·         Question: Review the number of shares traded on a weekly and monthly basis … is OTCQB: BSTG a Ponzi scheme (with their pump/promote buy and sell agenda) as shares are bought to replace those sold?

·         Accumulated deficit:  $85,901 M – still NO product in sight – a 4-to-5-year clinical trial BEFORE they can evolve to a pediatric protocol!

·         OTCQB: BSTG is holding their annual meeting on 7/19, to vote the Beijing, China designated directors …??? Certainly NOT a US company ANYMORE!

 

My question that resounds, that should be asked is how many companies are at the end of sentiments …  leash?

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.